[1] Gupta A K, Melton L R, Petersen G M, et al: Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study[J]. Clin Gastroenterol Hepatol 2005; 3(2): 150-158.
[2] Kyzer S, Begin L R, Gordon P H, et al: The care of patients with colorectal polyps that contain invasive adenocarcinoma. Endoscopic polypectomy or colectomy? Cancer 1992; 70(8): 2044-2050.
[3] Morson B C, Whiteway J E, Jones E A, et al: Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy[J]. Gut 1984; 25(5): 437-444.
[4] Watanabe T, Muro K, Ajioka Y, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer[J]. Int J Clin Oncol 2018; 23(1): 1-34.
[5] Kikuchi R, Takano M, Takagi K, et al: Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines[J]. Dis Colon Rectum 1995; 38(12): 1286-1295.
[6] Tominaga K, Nakanishi Y, Nimura S, et al: Predictive histopathologic factors for lymph node metastasis in patients with nonpedunculated submucosal invasive colorectal carcinoma[J]. Dis Colon Rectum 2005; 48(1): 92-100.
[7] Sohn D K, Chang H J, Park J W, et al: Histopathological risk factors for lymph node metastasis in submucosal invasive colorectal carcinoma of pedunculated or semipedunculated type[J]. J Clin Pathol 2007; 60(8): 912-915.
[8] Okabe S, Shia J, Nash G, et al: Lymph node metastasis in T1 adenocarcinoma of the colon and rectum[J]. J Gastrointest Surg 2004; 8(8): 1032-1040.
[9] Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015; 33(16):1787-1796.
[10] Machado I, Valera-Alberni M, Martínez de Juan F, et al: Histological factors predicting loco-regional lymph node metastasis in early invasive colorectal adenocarcinoma pT1. Gastroenterol Hepatol 2016; 39(1): 1-8.
[11] Krasna M J, Flancbaum L, Cody R P, et al: Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance[J]. Cancer 1988; 61(5): 1018-1023.
[12] Gangireddy VGR, Coleman T, Kanneganti P, et al: Polypectomy versus surgery in early colon cancer: size and location of colon cancer affect long-term survival. Int J Colorectal Dis 2018; 33 (10), 1349-1357.
[13] Zhang H, Chen CS, Cong JC, et al: Clinicopathological characteristics of advanced colorectal cancer 30 mm or smaller in diameter. Chin Med Sci J 2007; 22(2):98-103.
[14] Wang H S, Liang W Y, Lin T C, et al: Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis[J]. Dis Colon Rectum 2005; 48(6): 1182-1192.
[15] Yasuda K, Inomata M, Shiromizu A, et al: Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection[J]. Dis Colon Rectum 2007; 50(9): 1370-1376.
[16] Aldecoa I, Atares B, Tarragona J, et al: Molecularly determined total tumour load in lymph nodes of stage I-II colon cancer patients correlates with high-risk factors. A multicentre prospective study. Virchows Arch 2016; 469(4):385-394.
[17] Yamauchi H, Togashi K, Kawamura Y J, et al: Pathological predictors for lymph node metastasis in T1 colorectal cancer[J]. Surg Today 2008; 38(10): 905-910.
[18] Brown Ian S, Bettington Mark L, Bettington Andrew, et al: Adverse histological features in malignant colorectal polyps: a contemporary series of 239 cases. J Clin Pathol 2016; 69(4) :292-299.
[19] Sakuragi M, Togashi K, Konishi F, et al: Predictive factors for lymph node metastasis in T1 stage colorectal carcinomas[J]. Dis Colon Rectum 2003; 46(12): 1626-1632.
[20] Son HJ, Song SY, Lee WY, et al: Characteristics of early colorectal carcinoma with lymph node metastatic disease[J]. Hepatogastroenterology 2008; 55(85): 1293-1297.
[21] Tateishi Y, Nakanishi Y, Taniguchi H, et al: Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma[J]. Mod Pathol 2010; 23(8): 1068-1072.
[22] Choi P W, Yu C S, Jang S J, et al: Risk factors for lymph node metastasis in submucosal invasive colorectal cancer[J]. World J Surg 2008; 32(9): 2089-2094.
[23] Egashira Y, Yoshida T, Hirata I, et al: Analysis of pathological risk factors for lymph node metastasis of submucosal invasive colon cancer[J]. Mod Pathol 2004; 17(5): 503-511.
[24] Choi P W, Yu C S, Jang S J, et al: Risk factors for lymph node metastasis in submucosal invasive colorectal cancer[J]. World J Surg 2008; 32(9): 2089-2094.
[25] Williams J G, Pullan R D, Hill J, et al: Management of the malignant colorectal polyp: ACPGBI position statement[J]. Colorectal Dis 2013; Suppl 2: 1-38.
[26] Hassan C, Zullo A, Risio M, et al: Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis[J]. Dis Colon Rectum 2005; 48(8): 1588-1596.
[27] Beaton C, Twine C P, Williams G L, et al: Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer[J]. Colorectal Dis 2013; 15(7): 788-797.
[28] Oka S, Tanaka S, Nakadoi K, et al: Risk analysis of submucosal invasive rectal carcinomas for lymph node metastasis to expand indication criteria for endoscopic resection[J]. Dig Endosc 2013; 25 Suppl 2: 21-25.
[29] Suh J H, Han K S, Kim B C, et al: Predictors for lymph node metastasis in T1 colorectal cancer[J]. Endoscopy 2012; 44(6): 590-595.
[30] Shilei Wen, Jinhang Gao, Linhao Zhang, et al. p53 increase mitochondrial copy number via up-regulation of mitochondrial transcription factor A in colorectal cancer. Oncotarget 2016;7(46):75981-75995.
[31] Jin C. Kim, Young K. Cho, Seon A. Roh, et al. Blackwell Publishing Asia Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. Cancer Sci. 2008;99(7):1348-1354.
[32] C Hanski, E Riede, A Gratchev, et al. MUC2 Gene Suppression in Human Colorectal Carcinomas and Their Metastases: In Vitro Evidence of the Modulatory Role of DNA Methylation. Lab Invest. 1997;77(6):685-695.
[33] Eva Bandres, Xabier Agirre, Nerea Bitarte, Natalia Ramirez, Ruth Zarate, Jose Roman-Gomez, Felipe Prosper, Jesus Garcia-Foncillas. Epigenetic Regulation of microRNA Expression in Colorectal Cancer. Int J Cancer 2009;125(11):2737-2743.
[34] Provenzale D, Gupta S, Ahnen D J, et al: NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1. J Natl Compr Canc Netw 2018; 16(8): 939-949.
[35]Watanabe T, Muro K, Ajioka Y, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer[J]. International Journal of Clinical Oncology 2018; 23(1): 1-34.,.
[36]Benson AB, Venook AP, Al-Hawary MM, et al: NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw 2018; 16(4) :359-369.
[37] Seyed Reza Fatemi, Mohamad Amin Pourhoseingholi, Farshad Asadi, et al: Recurrence and Five -Year Survival in Colorectal Cancer Patients After Surgery. Iran J Cancer Prev 2015; 8(4): e3439.
[38] Hegde SR, Sun W, Lynch JP. Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2008;2(1):135-149.
[39] Michael A Morse, Howard Hochster, Al Benson. Perspectives on Treatment of Metastatic Colorectal Cancer With Immune Checkpoint Inhibitor Therapy. Oncologist 2020;25(1):33-45.